US 8530466
Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
granted A61KA61K31/5383A61K31/662
Quick answer
US patent 8530466 (Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Sep 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 1
- CPC classes
- A61K, A61K31/5383, A61K31/662, A61P, A61P43/00